| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 18,003 | 18,220 | ||
| Short-term investments | 43,918 | 44,696 | ||
| Prepaid expenses and other current assets | 2,095 | 4,608 | ||
| Total current assets | 64,016 | 67,524 | ||
| Long-term investments | 3,219 | 8,301 | ||
| Other assets, long-term | 0 | 0 | ||
| Total assets | 67,235 | 75,825 | ||
| Accounts payable | 2,226 | 2,113 | ||
| Accrued compensation | 1,744 | 1,199 | ||
| Accrued liabilities | 2,705 | 2,954 | ||
| Other current liabilities | 183 | 717 | ||
| Total liabilities | 6,858 | 6,983 | ||
| Additional paid-in capital | 292,553 | 291,704 | ||
| Accumulated other comprehensive gain | 64 | 25 | ||
| Accumulated deficit | -232,240 | -222,887 | ||
| Total stockholders' equity | 60,377 | 68,842 | ||
| Total liabilities and stockholders' equity | 67,235 | 75,825 | ||
AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. (ANTX)